The global cat therapeutic diet market size was estimated at USD 1.8 billion in 2025 and is projected to reach USD 3.6 billion by 2033, growing at a CAGR of 8.9% from 2026 to 2033. The market growth is driven by continuous innovation in specialized pet nutrition, enabling the development of more effective and condition-specific formulations.
This is further supported by the rising prevalence of chronic diseases in cats, which is increasing the need for targeted dietary interventions. In addition, the ongoing premiumization of pet food products, with a shift toward high-quality, scientifically formulated diets, is also contributing significantly to overall market expansion.
Advancements in microbiome science are playing a critical role in transforming therapeutic nutrition for pets, with leading companies introducing clinically backed innovations. For instance, Hill's Pet Nutrition showcased its latest developments at the Veterinary Meeting & Expo (VMX) 2025, highlighting new and enhanced Prescription Diet and Science Diet products powered by ActivBiome+ technology. This innovation is based on extensive microbiome research involving thousands of biological samples, enabling targeted nutritional interventions that actively support gut health. The technology includes specialized formulations such as ActivBiome+ Digestion for gastrointestinal support, ActivBiome+ Kidney Defense for reducing toxin buildup, and Multi-Benefit blends designed to enhance immune and organ health.
Moreover, the increasing prevalence of chronic and nutrition-related diseases in cats is significantly driving the demand for specialized dietary interventions. For instance, according to an article published by SKS Veterinary Hospital, in October 2025, among the conditions, obesity has emerged as one of the most common and clinically complex disorders in companion animals, particularly in urban environments where prevalence rates are estimated to reach 35-40%. Beyond excess weight, obesity is associated with metabolic dysfunction, hormonal imbalance, and a higher risk of secondary conditions such as diabetes, joint disorders, and cardiovascular complications. Although adoption is still evolving, there is a growing opportunity for clinically formulated weight-management diets, with around 35% of cat owners already incorporating therapeutic or prescription diets into their pets’ weight-loss programs.
Moreover, according to an article published by Merck & Co., Inc., diabetes is an increasingly recognized metabolic disorder in pets, affecting approximately 1 in 230 cats. This growing prevalence highlights the need for early diagnosis and structured disease management, as diabetes requires long-term control through a combination of veterinary care and specialized nutrition. This gap between disease prevalence and treatment adoption highlights a strong growth potential for the cat therapeutic diet industry. As veterinary awareness and diagnostic rates improve, there is a growing shift toward structured, diet-based management of obesity and its related conditions.
Furthermore, the increasing adoption of pet insurance is creating a strong opportunity for the cat therapeutic diet industry by improving affordability and encouraging veterinary-led treatment. For instance, policies offered through Asda Money cover veterinary consultations, diagnostics, medications, and treatments for new illnesses or injuries, which increases the likelihood of early diagnosis and clinical intervention. Importantly, these policies also include specialist or prescribed diet food under veterinary fee cover, typically within defined limits depending on the plan. This means that for conditions like GI issues, renal disease, or allergies, a portion of the cost of therapeutic or prescription diets may be covered as part of treatment, easing the financial burden on pet owners.
This product will be delivered within 1-3 business days.
This is further supported by the rising prevalence of chronic diseases in cats, which is increasing the need for targeted dietary interventions. In addition, the ongoing premiumization of pet food products, with a shift toward high-quality, scientifically formulated diets, is also contributing significantly to overall market expansion.
Advancements in microbiome science are playing a critical role in transforming therapeutic nutrition for pets, with leading companies introducing clinically backed innovations. For instance, Hill's Pet Nutrition showcased its latest developments at the Veterinary Meeting & Expo (VMX) 2025, highlighting new and enhanced Prescription Diet and Science Diet products powered by ActivBiome+ technology. This innovation is based on extensive microbiome research involving thousands of biological samples, enabling targeted nutritional interventions that actively support gut health. The technology includes specialized formulations such as ActivBiome+ Digestion for gastrointestinal support, ActivBiome+ Kidney Defense for reducing toxin buildup, and Multi-Benefit blends designed to enhance immune and organ health.
Moreover, the increasing prevalence of chronic and nutrition-related diseases in cats is significantly driving the demand for specialized dietary interventions. For instance, according to an article published by SKS Veterinary Hospital, in October 2025, among the conditions, obesity has emerged as one of the most common and clinically complex disorders in companion animals, particularly in urban environments where prevalence rates are estimated to reach 35-40%. Beyond excess weight, obesity is associated with metabolic dysfunction, hormonal imbalance, and a higher risk of secondary conditions such as diabetes, joint disorders, and cardiovascular complications. Although adoption is still evolving, there is a growing opportunity for clinically formulated weight-management diets, with around 35% of cat owners already incorporating therapeutic or prescription diets into their pets’ weight-loss programs.
Moreover, according to an article published by Merck & Co., Inc., diabetes is an increasingly recognized metabolic disorder in pets, affecting approximately 1 in 230 cats. This growing prevalence highlights the need for early diagnosis and structured disease management, as diabetes requires long-term control through a combination of veterinary care and specialized nutrition. This gap between disease prevalence and treatment adoption highlights a strong growth potential for the cat therapeutic diet industry. As veterinary awareness and diagnostic rates improve, there is a growing shift toward structured, diet-based management of obesity and its related conditions.
Furthermore, the increasing adoption of pet insurance is creating a strong opportunity for the cat therapeutic diet industry by improving affordability and encouraging veterinary-led treatment. For instance, policies offered through Asda Money cover veterinary consultations, diagnostics, medications, and treatments for new illnesses or injuries, which increases the likelihood of early diagnosis and clinical intervention. Importantly, these policies also include specialist or prescribed diet food under veterinary fee cover, typically within defined limits depending on the plan. This means that for conditions like GI issues, renal disease, or allergies, a portion of the cost of therapeutic or prescription diets may be covered as part of treatment, easing the financial burden on pet owners.
Global Cat Therapeutic Diet Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global cat therapeutic diet market report based on product, indication, distribution channel, and region.Product Outlook (Revenue, USD Million, 2021-2033)
- Wet Food
- Dry Food
- Others
Indication Outlook (Revenue, USD Million, 2021-2033)
- Renal Care
- Obesity Care
- Diabetic Care
- Dental Care
- Gastrointestinal Care
- Recovery Care
- Joint Care
- Oncology Care
- Others
Distribution Channel Outlook (Revenue, USD Million, 2021-2033)
- E-commerce
- Veterinary hospitals & clinics
- Retail Pharmacies
- Others
Region Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Kuwait
- Qatar
- Oman
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variable Trends & Scope
Chapter 4. Cat Therapeutic Diet Market: by Product Estimates & Trend Analysis
Chapter 5. Cat Therapeutic Diet Market: by Indication Estimates & Trend Analysis
Chapter 6. Cat Therapeutic Diet Market: by Distribution Channel Estimates & Trend Analysis
Chapter 7. Cat Therapeutic Diet Market: by Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Colgate-Palmolive Company (Hill's Pet Nutrition Inc.)
- Nestlé
- Mars Petcare (Royal Canin)
- General Mills Inc. (Blue Buffalo Company, Ltd.)
- Diamond Pet Foods, Inc.
- Virbac
- VNG (Veterinary Nutrition Group)
- Farmina Pet Foods USA
- EmerAid
- TROVET
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 1.8 Billion |
| Forecasted Market Value ( USD | $ 3.6 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
